What is ProciseDx?
Founded in 2018 and headquartered in San Diego, California, ProciseDx is a diagnostics company focused on developing and commercializing a comprehensive suite of point-of-care diagnostic tests. These tests are designed for deployment in various clinical settings, including physician offices, retail clinics, and urgent care centers, aiming to enhance accessibility and efficiency in diagnostic procedures. The company's commitment lies in advancing diagnostic capabilities at the point of care.
How much funding has ProciseDx raised?
ProciseDx has raised a total of $10.5M across 1 funding round:
Series A
$10.5M
Series A (2020): $10.5M with participation from Nestle Health Science and Biosynex
Key Investors in ProciseDx
Nestle Health Science
Nestle Health Science is a global leader in nutrition and health, likely investing in ProciseDx to enhance its portfolio of diagnostic solutions that align with health and wellness objectives.
Biosynex
Biosynex is a company specializing in rapid diagnostic tests, suggesting a strategic interest in ProciseDx's point-of-care diagnostic technologies and market expansion.
What's next for ProciseDx?
The recent major strategic investment signifies a pivotal moment for ProciseDx, likely enabling the company to accelerate its product development pipeline, expand its commercial reach, and further solidify its market position. This capital infusion is expected to fuel innovation in point-of-care diagnostics, potentially leading to new test introductions and broader adoption across healthcare providers. The company's focus on accessible diagnostics positions it for continued expansion in a growing market.
See full ProciseDx company page
